slide1
Download
Skip this Video
Download Presentation
Trastuzumab plus chemotherapy: the gold standard for HER2 positive early breast cancer

Loading in 2 Seconds...

play fullscreen
1 / 60

Trastuzumab plus chemotherapy: the gold standard for HER2 positive early breast cancer - PowerPoint PPT Presentation


  • 293 Views
  • Uploaded on

Current status of adjuvant HER2 targeting therapy Valentina Guarneri, MD, PhD Istituto Oncologico Veneto IRCCS University of Padova. Outline. Trastuzumab plus chemotherapy: the gold standard for HER2 positive early breast cancer

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Trastuzumab plus chemotherapy: the gold standard for HER2 positive early breast cancer' - ama


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Current status of adjuvant HER2 targeting therapyValentina Guarneri, MD, PhDIstituto Oncologico Veneto IRCCSUniversity of Padova

slide2

Outline

  • Trastuzumab plus chemotherapy: the gold standard for HER2 positive early breast cancer
  • Improving on cardiac toxicity: different regimens and different treatment durations
  • Improving on treatment efficacy: dual blockade and new anti-HER2 agents
  • Toward personalized cancer medicine: challenging the gold standard for specific patient subgroups
slide3

Outline

  • Trastuzumab plus chemotherapy: the gold standard for HER2 positive early breast cancer
  • Improving on cardiac toxicity: different regimens and different treatment durations
  • Improving on treatment efficacy: dual blockade and new anti-HER2 agents
  • Toward personalized cancer medicine: challenging the gold standard for specific patient subgroups
slide5

Meta-analysis of adjuvant trastuzumab trials: Disease-free Survival

MojaL, et al. The CochraneLibrary 2012, Issue4

slide6

Meta-analysis of adjuvant trastuzumab trials: Overall Survival

MojaL, et al. The CochraneLibrary 2012, Issue4

slide7

DFS : ∆ 11.9% at 6y

∆ 11.5% at 10y

OS : ∆ 5.5% at 6y

∆ 8.8% at 10y

are all trastuzumab adjuvant trials the same

Sequentialadministration

Concurrentadministration

Trastuzumab up to 1 yr

BCIRG 006

DC x 6+ H

AC x 4

D x 4+ H

Joint analysis of

NSABP B31 & N9831

AC x 4

T x 4 + H

N9831

Sequential arm

wT x 12

AC x 4

HERA

Adjuvant CT (Any)

RT

FIN-HER

D/N+H x 9 wks

FECx 3

FEC/ED x 6

RT

PACS 04

Are all trastuzumab adjuvant trials the same?

Randomization

Trastuzumab start

T= paclitaxel; D= docetaxel

slide9

Overall Survival stratified by concurrent or sequential administration

MojaL, et al. The CochraneLibrary 2012, Issue4

slide12

Outline

  • Trastuzumab plus chemotherapy: the gold standard for HER2 positive early breast cancer
  • Improving on cardiac toxicity: different regimens and different treatment durations
  • Improving on treatment efficacy: dual blockade and new anti-HER2 agents
  • Toward personalized cancer medicine: challenging the gold standard for specific patient subgroups
slide13

High competing mortality risk score

Low competing mortality risk score

Cancer ahead pub 2010

congestive heart failure chf all studies
Congestive heart failure (CHF): all studies.

Moja L, et al. The Cochrane Library 2012, Issue 4

slide16

BCIRG 006: Adjuvant Breast Cancer

Node Positive and High Risk Node Negative

4x AC60/600 mg/m2

4x Docetaxel

100 mg/m2

ACT

HER2+

(central FISH)

N+ or

High risk N-

N=3,222 pts

ACTH

1 Year Trastuzumab

6 x Docetaxel 75 mg/m2

+Carboplatin AUC 6

TCH

1 Year Trastuzumab

slide20

CHF by trastuzumab duration

Moja L, et al. The Cochrane Library 2012, Issue 4

dfs by trastuzumab duration
DFS by trastuzumab duration

Log (Hazard ratio) HR weight HR (IV,random, 95%CI)

Moja L, et al. The Cochrane Library 2012

overall survival stratified by duration of trastuzumab treatment
Overall survival stratified by duration of trastuzumab treatment

Moja L, et al. The Cochrane Library 2012, Issue 4

slide29

PHARE* Trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancerXavier Pivot, Gilles Romieu, Hervé Bonnefoi, Jean-Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel Serin,Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-Lacourtoisie, Nicole Tubiana-Mathieu, Laurent Cany, Stéphanie Catala, David Khayat, Iris Pauporté, Andrew Kramar.

  • Protocol of
  • Herceptin®
  • Adjuvant with
  • Reduced
  • Exposure
  • *lighthouse in French
study design
Study design

trastuzumab up to 12 months

trastuzumab 6 months

R

Stratification

1. ER pos / neg

2. Chemo: conco/ seq

stop trastuzumab

Clinical exam

LVEF

0

3

6

9

12

15

18

21

24

30 mos

Mammography

Up to 60 mos…

R: Randomizationafterinformed consent

statistical methods
Statistical Methods
  • Non inferiorityrandomized trial
  • 2% variation in terms of absolutedifference of recurrence
  • The 95% CI HR marginsshould not cross the 1.15 boundary
  • 1040 DFS events required for 80% power at 5% level

or

4 years of accrual and at least 2 years of follow-up

  • HR were estimated from the stratified Cox model
  • Accrualtarget: 3400 patients
primary endpoint scenarii
Primary endpoint scenarii

A

Equivalent

B

Superior

C

D

Non Inferior

E

Inferior

.85

1

1.15

1.3

1.45

1.6

HR

cardiac toxicity
Cardiac toxicity

* Investigatorreportedevents (composite withclinical and LFEV finding)

** Based on more than > 25,000 assessments

dfs events
DFS Events

42.5mos. median Follow-up

disease free survival
Disease Free Survival

97.0 93.8 90.7 87.8

95.5 91.2 87.8 84.9

EventsHR95%CIp-value

H 12m 176

H 6m 219 1.28 (1.05 – 1.56) 0.29

* Cox model stratified by ER status and concomitant chemotherapy

overall survival

42.5mos. median FU

Overall Survival

99.9 98.7 96.9 95.0

99.3 97.2 95.2 93.1

EventsHR95%CIp-value

H 12m 66

H 6m 93 1.47 (1.07 – 2.02)

* Cox model stratified by ER status and concomitant chemotherapy

primary endpoint scenarii1
Primary endpoint scenarii

A

Equivalent

B

Superior

PHARE trial

C

D

Non Inferior

E

Inferior

.85

1

1.15

1.3

1.45

1.6

HR

trastuzumab duration effects in patient subgroups in the phare trial

Trastuzumab duration effects in patient subgroups in the PHARE*trial

  • Protocol of
  • Herceptin®
  • Adjuvant with
  • Reduced
  • Exposure

Xavier Pivot, Gilles Romieu, Hervé Bonnefoi, Jean-Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel Serin,Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-Lacourtoisie, Nicole Tubiana-Mathieu, Laurent Cany, Stéphanie Catala, David Khayat, Iris Pauporté, Andrew Kramar.

SABCS 2012

  • *lighthouse in French
slide41

Subgroup Results

ER- status &

Sequentialmodality

Other groups

slide42

R

9 mos

3 mos

6 mos

12 mos

Trastuzumab 8 mg/kg

loading dose  6 mg/kg q 3 wks

AC60/600 or

EC90/600

Docetaxel 100

FEC (600/60/600)

Trastuzumab 4 mg/kg

loading dose 2 mg/kg weekly

:LVEF measurement

Short-HER: study design

PI: PF Conte

RT/HT

Sample size 1250 pts

RT/HT

18 mos

EUDRACT-2007-004326-25, NCT00629278

enrollment as of may 2013
Enrollment as of May, 2013
  • 1176 patients
    • Arm A (Long) 586 patients
    • Arm B (Short) 590 patients
slide44

Outline

  • Trastuzumab plus chemotherapy: the gold standard for HER2 positive early breast cancer
  • Improving on cardiac toxicity: different regimens and different treatment durations
  • Improving on treatment efficacy: new anti-HER2 agents and multiple dual blockade
  • Toward personalized cancer medicine: challenging the gold standard for specific patient subgroups
teach trial
TEACH Trial
  • Eligibility
  • HER2+ Local IHC3+ or FISH +ve
  • Resected Stage I-IIIc primary BRCA
  • No prior trastuzumab
  • Neo-/adjuvant chemotherapy (CMF, anthracycline, or taxane)
  • Appropriate endocrine therapy
  • Stratification
  • Time from diagnosis ≤4 vs >4 yrs
  • Lymph node +ve vs -ve
  • ER+ and/or PgR+ vs ER–/PgR–

R

A

N

D

O

M

I

Z

E

Lapatinib

1500 mg qd × 1 yr

N=3147

Aug 2006-May 2008

33 countries

Placebo

qd × 1 yr

4 yr

Diagnosis

  • Disease-free survival (DFS):local, regional, distant recurrence,contralateralBRCA,other 2nd primary cancers,death from any cause

Goss, SABCS 2011

teach primary endpoint k m plot of dfs in itt population time from randomization
TEACH Primary Endpoint: K-M Plot of DFS inITT Population—Time From Randomization

Lapatinib

HR 0.83 (0.70-1.00); p=0.053a

Placebo

Median Follow up: 4 years

0.0

  • No improvement in OS demonstrated with use of lapatinib:HR: 0.99 (95% CI: 0.74-1.31; P = .966)

Goss, SABCS 2011

ap value based on 2-sided stratified log-rank test

teach forest plot of dfs for subgroups in itt population
TEACH: Forest Plot of DFS for Subgroups in ITT Population

L=lapatinib; P=placebo.

Goss, SABCS 2011

slide48

Dual anti-HER2 blockade

(neoadjuvant studies)

Phase III NeoALLTO study

Phase II CHER-LOB study

slide49

Dual Anti-HER2 blockade significantly increases the pCR rate

60

Exploratory p=0.0187

50

40

46.7%

30

20

25%

26.3%

10

0

Arm A: CT + T

Arm B: CT + L

Arm C: CT + T + L

pCR (breast & axilla)

Guarneri V et al, J Clin Oncol 2012

Baselga J et al. Lancet 2012

aphynity
Aphynity

R

IBCSG 39-11 / BIG 4-11 (APHINITY)

HER2+ BC

N+ or high-risk N0

6-8 cycles

Adj CHT

6-8 cycles

Adj CHT

52 weeks

Expectedenrollment: 3806 pts

Trastuzumab i.v.8 mg/kg LD then6 mg/kg, q3w

Pertuzumab 840 mg i.v. LD then 420 mg, q3w

T, P/Pl concomitant to taxane-based CT

Placebo i.v., q3w

slide54

Outline

  • Trastuzumab plus chemotherapy: the gold standard for HER2 positive early breast cancer
  • Improving on cardiac toxicity: different regimens and different treatment durations
  • Improving on treatment efficacy: dual blockade and new anti-HER2 agents
  • Toward personalized cancer medicine: challenging the gold standard for specific patient subgroups
trastuzumab adjuvant trials subset analysis
Trastuzumab Adjuvant trials: subset analysis

N–

HERA

32 % N0

1–3+ nodes

≥4+ nodes

Not assessed

7% N0

N9831/B-31

N–

1–3+ nodes

4–9+ nodes

>10+ nodes

BCIRG 006

29% N0

N–

ACTH

N+

29% N0

N–

TCH

N+

0

0.5

1.0

1.5

2.0

2.5

HR

Favours trastuzumab

Favours no trastuzumab

Slamon, et al. SABCS 2006 Perez, et al. ASCO 2007; Smith, et al. Lancet 2007

N = node

slide57

HER2+ EBC patients

Adjuvanttrastuzumabtrials vs Modena CancerRegistry

Piccart N Engl J Med 2005; Romond N Engl J Med 2005; Joensuu N Engl J Med 2006; Slamon D, SABCS 2006; Spielmann M et al, SABCS 2007; Federico M, RTM 1998-2009

slide58

pCR by Hormone Receptor Status

Baselga J et al. SABCS 2010; Gianni et al, SABCS 2010, Guarneri et al, ASCO 2011

slide60

Summary of HER2+ EBC

  • CT+ 1yr trastuzumab is the standard regimen
  • Studiesevaluatingoptimal trastuzumab duration in termsofefficacy and safety are critical:
    • to take into account the sustainabilityfor the NHS
    • to facilitate the introductionofnew antiHER2 treatments
  • Neoadjuvant studies are essentialtorank treatment activity, priortomovetolargeadjuvantstudies
  • A dualHER2 inhibitionseems a winnerstrategy
  • New promisingagents are entering the adjuvantphase
  • The possibilitytoavoidchemotherapy in case ofsmallTsize, N0, HR+, elderly and frailpatientsisintriguing, butstillmatterofstudy
ad